Surasak Phuphanich
Publications by Year
Research Areas
Glioma Diagnosis and Treatment, Immunotherapy and Immune Responses, Brain Metastases and Treatment, RNA Interference and Gene Delivery, CAR-T cell therapy research
Most-Cited Works
- → Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma(2020)1,394 cited
- → Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma(2013)590 cited
- A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.(1999)
- → Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme(2010)452 cited
- → A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting(2004)437 cited
- → Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis(1999)398 cited
- → Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma(2012)381 cited
- → OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143(2017)315 cited
- → A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma(2019)265 cited
- → The current state of molecular testing in the treatment of patients with solid tumors, 2019(2019)258 cited